Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This regenerative cell therapy is a combination product developed through a collaboration between Evotec and Sernova. It integrates Sernova's **Cell Pouch System**, an implantable medical device, with Evotec's induced pluripotent stem cell (iPSC)-derived islet-like clusters. The Cell Pouch is designed to be implanted subcutaneously where it becomes vascularized, creating a natural environment for the subsequent transplantation of therapeutic cells. The active biological component consists of iPSC-derived clusters containing insulin-producing beta cells, glucagon-producing alpha cells, and somatostatin-producing delta cells. This therapy aims to restore endogenous glycemic control and physiological hormone regulation in patients with insulin-dependent diabetes, potentially providing a functional cure for both Type 1 and Type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iPSC-derived islet-like clusters + Cell Pouch.